Table 1: Characteristics of patients on biological therapy.

- Omalizumab Mepolizumab Benralizumab Dupilumab
n 183 11 22 54
F:M 119:64 8:3 12:10 32:22
Age
Median (IQR)
35 (28.5-43) 42 (32-79) 44.5 (15-64) 39 (16-78)
Indications (n) -Chronic Urticaria (148) -Asthma (7)   -Asthma (39)
-Asthma (31) -EGPA (3) Asthma (22) -Dermatitis (13)
EGPA (3) -Eosinophilic cystitis (1)   -Chronic rhinosinusitis with nasal polyposis (2)
-ABPA (1)      
Mean Dose Frequency (weeks) 4.4 4 8 2.2
Mean Dosage (mg) 311.1 172.7 30 300
Adverse Effects (n) -Pruritus (2)      
-Urticaria (1) None reported Migraines (1) Pruritus + Dizziness (1)
-Vasovagal reaction (1)